Blog Post > News > Uncategorized > Findings support repurposing rheumatoid arthritis drug auranofin for diabetes – Medical Xpress

Findings support repurposing rheumatoid arthritis drug auranofin for diabetes – Medical Xpress

Forget Password?
Learn more
share this!
October 14, 2022
Researchers at Baylor College of Medicine and collaborating institutions discovered that the rheumatoid arthritis drug auranofin can potentially be repurposed to improve diabetes-associated symptoms. The study, which was conducted in mice, appeared today in the journal Cell Metabolism.

googletag.cmd.push(function() { googletag.display(‘div-gpt-ad-1450190541376-1’); });

Although scientists have identified definitive associations between inflammation in and insulin resistance in humans and rodents, broad anti-inflammatory treatments lack durable clinical efficacy on diabetes. In the current study, the researchers explored in more detail this association between inflammation and diabetes by looking for existing drugs that might affect both conditions.
“We computationally screened a small-molecule dataset and identified auranofin, an FDA-approved drug that has been used to treat , a condition involving inflammation,” said first and co-corresponding author Dr. Aaron R. Cox, instructor of medicine-endocrinology, diabetes and metabolism at Baylor. “Auranofin exerts anti-inflammatory properties, which many people suspected would be beneficial in obesity and diabetes; however, nothing was really known about how it might affect metabolism.”
The team evaluated the metabolic effects of auranofin in a mouse model of diabetes in which the animals consume a .
“We discovered that auranofin has anti-inflammatory and anti-diabetic effects that are independent from each other,” said co-corresponding author Dr. Sean Hartig, associate professor of medicine-endocrinology, diabetes and metabolism and molecular and cellular biology at Baylor. Hartig also is a member of Baylor’s Dan L Duncan Comprehensive Cancer Center.
“Auranofin improved insulin sensitivity, or the body’s ability to respond to insulin to keep at healthy levels. The drug also normalized obesity-associated changes such as hyperinsulinemia—blood insulin levels that are higher than normal—in the mouse model. In addition, we found that auranofin accumulation in white adipose tissue reduced inflammatory responses without altering body composition in obese mice.”
Looking into the mechanism of these metabolic changes, the team discovered that the anti-diabetic effects of auranofin involved reduction of leptin levels. Leptin is a hormone whose levels markedly increase in obesity, contributing to and diabetes. In addition, auranofin restored white adipose tissue’s ability to respond to catecholamines, which are signals that increase metabolic activities in adipose tissue, triggering the burning of lipids at a higher rate.
“These changes coupled together contribute to the overall improvement in of the mice, leading to blood glucose control, which is the ultimate goal of diabetes treatments,” Cox said. “High levels of glucose in the blood are detrimental to many tissues in the body. Uncontrolled, can lead to organ failure.”
“We are very excited about these findings; however, more research will be needed to determine an to translate them to the clinic,” said Hartig.

Explore further

Combined therapy for diabetes improves effect of insulin-alternative in mice

More information: Sean M. Hartig, The rheumatoid arthritis drug auranofin lowers leptin levels and exerts anti-diabetic effects in obese mice, Cell Metabolism (2022). DOI: 10.1016/j.cmet.2022.09.019. … 1550-4131(22)00409-0

Journal information: Cell Metabolism

Citation: Findings support repurposing rheumatoid arthritis drug auranofin for diabetes (2022, October 14) retrieved 14 October 2022 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further
Feedback to editors
Oct 13, 2022
Oct 13, 2022
Oct 11, 2022
Oct 10, 2022
Oct 07, 2022
13 minutes ago
30 minutes ago
36 minutes ago
54 minutes ago
1 hour ago
1 hour ago
1 hour ago
Sep 14, 2022
Aug 14, 2018
Jun 27, 2022
Feb 15, 2022
Jun 14, 2022
Jun 11, 2019
23 hours ago
23 hours ago
Oct 13, 2022
Oct 13, 2022
Oct 12, 2022
Oct 11, 2022
Use this form if you have come across a typo, inaccuracy or would like to send an edit request for the content on this page. For general inquiries, please use our contact form. For general feedback, use the public comments section below (please adhere to guidelines).
Please select the most appropriate category to facilitate processing of your request
Thank you for taking time to provide your feedback to the editors.
Your feedback is important to us. However, we do not guarantee individual replies due to the high volume of messages.
Your email address is used only to let the recipient know who sent the email. Neither your address nor the recipient’s address will be used for any other purpose. The information you enter will appear in your e-mail message and is not retained by Medical Xpress in any form.

Get weekly and/or daily updates delivered to your inbox. You can unsubscribe at any time and we’ll never share your details to third parties.
More information Privacy policy
Daily science news on research developments and the latest scientific innovations
The latest engineering, electronics and technology advances
The most comprehensive sci-tech news coverage on the web
This site uses cookies to assist with navigation, analyse your use of our services, collect data for ads personalisation and provide content from third parties. By using our site, you acknowledge that you have read and understand our Privacy Policy and Terms of Use.


Leave a comment

Your email address will not be published. Required fields are marked *

Chat with us

Hi there! How can I help you?